396 related articles for article (PubMed ID: 30828788)
1. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
4. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
5. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.
Sugawara T; Lejeune P; Köhr S; Neuhaus R; Faus H; Gelato KA; Busemann M; Cleve A; Lücking U; von Nussbaum F; Brands M; Mumberg D; Jung K; Stephan C; Haendler B
Oncotarget; 2016 Feb; 7(5):6015-28. PubMed ID: 26760770
[TBL] [Abstract][Full Text] [Related]
6. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
7. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
9. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
[TBL] [Abstract][Full Text] [Related]
11. Darolutamide: First Approval.
Markham A; Duggan S
Drugs; 2019 Nov; 79(16):1813-1818. PubMed ID: 31605368
[TBL] [Abstract][Full Text] [Related]
12. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
[No Abstract] [Full Text] [Related]
13. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
14. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
[TBL] [Abstract][Full Text] [Related]
16. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
17. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
18. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
19. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
20. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
